SlideShare une entreprise Scribd logo
1  sur  25
SCHIZOPHRENIA FROM FIRST-
EPISODE
COHORTS: SYSTEMATIC REVIEW
AND
META-ANALYSIS
Dr. Robert Ferris & Dr. Daere Akobo
Journal Review
Background
 Lifetime prevalence of schizophrenia is 7 per
1000 people6
 Not all patients respond to 1st line
antipsychotic medication; poor response to
treatment leads to a diagnosis of Treatment-
Resistant Schizophrenia (TRS)
 TRS is associated with high levels of
functional impairment8, healthcare usage,
societal costs9 and physical health
comorbidity10
Background
 A consensus definition of TRS has been
developed by the Treatment-Resistant
Schizophrenia: Treatment Response and
Resistance in Psychosis (TRRIP) Working
Group3, which includes the following:
 Current symptoms of at least moderate severity
and moderate or worse functional impairment
 Prior treatment with at least two different
antipsychotics, each for at least 4–6 weeks
minimum duration at total daily dose equivalent of
at least 600mg chlorpromazine
Treatment-Resistant Schizophrenia
(TRS)
 There remains a lack of clarity as to the proportion of
patients with TRS
 The most effective medication for TRS is clozapine,
which offers
 Improvement in positive symptoms7
 Improved rates of hospital admissions11
 Decreased overall mortality12
 Clozapine use, due to its potential adverse-effects, is
typically limited to patients who have had ≥2 previous
failed responses to first-line antipsychotics
 Implementation of clozapine therapy is, therefore,
sometimes regarded as an indicator of TRS1
 Regional differences in rates of clozapine prescribing
negatively affects its use as a proxy for TRS rates
The Study1
The Study1
 Quantifying the rates of patients with TRS may
highlight the need to improve access to clozapine and
increase opportunities of a clozapine trial for patients
with TRS
 Cross-sectional studies examining the proportion of
patients with TRS may overestimate the true rate
because of selection bias
 In contrast, longitudinal first-episode cohort studies
may more accurately quantify the incidence of
patients with TRS
 However, first-episode cohort studies from single sites may
not be generalisable
 Combination of first-episode cohorts from multiple sites
provides more robust data set
The Study1
 Literature was systematically reviewed with
this in mind
 Longitudinal cohort studies of people with First-
Episode Psychosis (FEP) and First-Episode
Schizophrenia (FES)
 The proportion that met criteria for TRS at
follow-up were identified, then meta-analysis
was performed in order to quantify rates of
TRS
Inclusion Criteria
 Cohort studies of individuals with FEP or FES
who were diagnosed according to DSM-IV,
DSM-5 or ICD-10 classifications
 Presence of clear definition of (TRS)
consistent with the TRRIP Working Group’s
standardised definition3
 Presence of longitudinal information on
pharmacological interventions
 Reports on the proportion of the FEP/FES
population who went on to develop a
treatment-resistant form of the illness
 Follow-up period of at least 8 weeks
Exclusion Criteria
 Papers with >75% overlap of included data-sets
with another paper
 Study populations which had already been
exposed to previous antipsychotic treatment
before entry into the cohort
 Where substance-induced psychosis could not be
excluded at time of follow-up
 Study designs that did not specifically capture all
sequential first-episode patients, such as cross-
sectional or randomised controlled trials, were
excluded as it could not be ascertained if the
criteria for participation in these studies
constituted a selection bias
Methodology
 Systematic review and meta-analysis
 8,273 citations, ultimately yielding 12 clinical
trials deemed fit for inclusion, including 1
unpublished data set
 These studies covered a total of 11,958
individuals
 Studies from Canada (n = 2), Denmark (n = 1),
England (n = 2), Japan (n = 1), Turkey (n = 1),
India (n = 1), USA (n = 1) and Ireland (n = 1);
two studies had multiple international locations
 Proportion of male study participants was 61.9%
(SD 10.4%)
Methodology
 Median duration of follow-up 26 months
(range 2–120 months)
 Nine cohorts comprised participants with
FES and three cohorts comprised
participants with FEP
 Nine studies used prospective data
collection; data for the remaining three was
collected retrospectively
 Two studies provided data on involuntary
treatment status
Included Trials
Data Extraction and Publication
Bias
 Two authors independently extracted data,
which was validated by two other authors from
the research team
 Publication bias was explored using funnel pot
asymmetry testing for statistical significance
with both Kendall’s τ and Egger’s regression
when meta-analyses included ≥10 studies
Results
 Overall rate of TRS was 22.8% (95% CI
19.1–27.0%, P < 0.001, I2 = 91.8%)
 Rates of TRS were significantly lower in FEP
cohorts compared with FES cohorts (17.8%
vs. 24.4%, P = 0.046)
Results
Discussion
 Rate of TRS was 22.8% in combined FEP
and FES cohorts, rising to 24.4% when only
FES cohorts included
 Rates of TRS were significantly lower in FEP
cohorts compared with FES cohorts (17.8%
vs. 24.4%, P = 0.046)
Discussion
 Men 1.5 times as likely as women to develop
TRS (95% CI 1.11–2.21, P = 0.010, I2 = 74%)
 In keeping with previous findings that men are one and
a half times more likely to develop schizophrenia than
women4
 Males generally diagnosed at a younger age5
Critical Appraisal
 Measured using the Critical Appraisal Skills
Programme (CASP) Checklist for Systematic
Review13
 10-question tool for appraisal of systematic review
Section A: Are the results valid?
1. Did the review address a clearly focused
question?
 YES: the review sought to measure rates of TRS
from FEP and FES presentations
2. Did the authors look for the right type of papers?
 YES: All were cohort studies, appropriate for
assessing single defined outcome from defined
populations
3. Do you think all the important, relevant studies
were included?
 YES: The authors utilised several different
databases; PubMed, PsycINFO, EMBASE, CINAHL
and the Cochrane Database of Systematic Reviews,
including unpublished data
Section A: Are the results valid?
4. Did the review’s authors do enough to assess quality
of the included studies?
 YES: Studies were assessed as low risk of bias and high
strength of reporting (three or more points), or high risk of
bias and low strength of reporting (fewer than three points)
using modified Newcastle–Ottawa Scale
 Six of twelve included studies were deemed to be of high
quality
 Only English-language studies were used
5. If the results of the review have been combined, was
it reasonable to do so?
 CAN’T TELL: All were similar study types, examining
common outcomes
 However, there was a mix of prospective and
retrospective used (retrospective more prone to bias)
Section B: What are the
results?
6. What are the overall results of the review?
 As previously-described, rates of TRS are provided as
percentage values of measured cohorts, and also
divided based on FEP vs. FES presentations
 Overall rate of TRS was 22.8%
 Rates of TRS in FEP cohorts 17.8% vs. 24.4% in FES
cohorts
7. How precise are the results?
 95% CI 19.1–27.0%, P < 0.001, I2 = 91.8%
 Study examines progression from both FEP and FES
only: rates of TRS in those with pre-existing
diagnoses not captured
Section C: Will the results help
locally?
8. Can the results be applied to the local
population?
 YES: authors posit that “Early identification of
people with FES who fail to respond to first or
second antipsychotic trials can assist in timely
provision of evidence-based treatments for TRS
such as clozapine”
 In Ireland, clozapine treatment is widely available,
and its use may be considered a reliable indicator
for TRS
 These results indicate benefits of prompt use
 However, potential contributing factors which may
Section C: Will the results help
locally?
9. Were all important outcomes considered?
 CAN’T TELL: Contributors of lost-to-follow-up
cohort? Concomitant diagnoses? Involuntary
admission status?
 Unclear to what extent these would effect
outcomes
10. Are the benefits worth the harms and costs?
 YES: Meta-analysis of TRS rates from first
presentation
 No harms/costs apparent from measurement
alone
Reference
s
1. Siskind D., Orr S. et al. (2022), ‘Rates of treatment-resistant schizophrenia
from first-episode cohorts: systematic review and meta-analysis’, BJPsych
220: 115–120. doi: 10.1192/bjp.2021.61
2. Psycom.net, ‘Schizophrenia’, accessed at
https://www.psycom.net/schizophrenia on 12/05/2022
3. Howes O.D., McCutcheon R. et al. (2017), ‘Treatment-Resistant
Schizophrenia: Treatment Response and Resistance in Psychosis
(TRRIP) Working Group consensus guidelines on diagnosis and
terminology’, Am J Psychiatry 174(3): 216–29
4. Aleman A., Kahn R.S., Selten J-P. (2003), ‘Sex differences in the risk of
schizophrenia: evidence from meta-analysis’, Arch Gen Psychiatry 60(6):
565–71
5. Sommer I.E., Tiihonen J et al. (2020), ‘The clinical course of schizophrenia
in women and men—a nation-wide cohort study’, NPJ Schizophr 6: 12
6. Saha S., Chant D. et al. (2005), ‘A systematic review of the prevalence of
schizophrenia’, PLoS Med 2(5): e141
7. Siskind D., McCartney L. et al. (2016), ‘Clozapine v. first-and second
generation antipsychotics in treatment-refractory schizophrenia:
systematic review and meta-analysis’, Br J Psychiatry 209(5): 385–92
Thank
you.
References (contd.)
8. Lasevoli F., Giordano S. et al. (2016), ‘Treatment resistant schizophrenia is
associated with the worst community functioning among severely-ill highly-
disabling psychiatric conditions and is the most relevant predictor of poorer
achievements in functional milestones’, Prog Neuropsychopharmacol Biol
Psychiatry 65: 34–48
9. Kennedy J.L., Altar C.A. et al. (2014), ‘The social and economic burden of
treatment-resistant schizophrenia: a systematic literature review’, Int Clin
Psychopharmacol 29(2): 63–76
10. Firth J., Siddiqi N. et al. (2019), ‘The Lancet Psychiatry Commission: a blueprint for
protecting physical health in people with mental illness’, Lancet Psychiatry 6(8):
675–712
11. Land R., Siskind D. et al. (2017), ‘The impact of clozapine on hospital use: a
systematic review and meta-analysis’, Acta Psychiatr. Scand. 135(4): 296–309
12. Vermeulen J.M., van Rooijen G. et al. (2019), ‘Clozapine and long-term mortality
risk in patients with schizophrenia: a systematic review and meta-analysis of
studies lasting 1.1–12.5 years’, Schizophr Bull 45(2): 315–29
13. Critical Appraisal Skills Programme (2018), ‘CASP Systematic Review Checklist’,
accessed at https://casp-uk.b-cdn.net/wp-content/uploads/2018/03/CASP-
Systematic-Review-Checklist-2018_fillable-form.pdf on 23/05/2022
Thank
you.

Contenu connexe

Similaire à Journal Review: Rates of Treatment-Resistant Schizophrenia from First-Episode Cohorts - Systematic Review and Meta-Analysis

Master of Public Health.pdf
Master of Public Health.pdfMaster of Public Health.pdf
Master of Public Health.pdfbkbk37
 
systematic review and metaanalysis
systematic review and metaanalysis systematic review and metaanalysis
systematic review and metaanalysis DrSridevi NH
 
Christoph Correll
Christoph CorrellChristoph Correll
Christoph Correllwef
 
HLT 362V Inspiring Innovation/tutorialrank.com
 HLT 362V Inspiring Innovation/tutorialrank.com  HLT 362V Inspiring Innovation/tutorialrank.com
HLT 362V Inspiring Innovation/tutorialrank.com jonhson133
 
HLT 362V Education Organization - snaptutorial.com
HLT 362V  Education Organization - snaptutorial.comHLT 362V  Education Organization - snaptutorial.com
HLT 362V Education Organization - snaptutorial.comdonaldzs199
 
Christy Starr Denman Poster
Christy Starr Denman PosterChristy Starr Denman Poster
Christy Starr Denman PosterChristy Starr
 
Presentation: Medicinal Cannabis Evidence for Efficacy Clinical Guidance Deve...
Presentation: Medicinal Cannabis Evidence for Efficacy Clinical Guidance Deve...Presentation: Medicinal Cannabis Evidence for Efficacy Clinical Guidance Deve...
Presentation: Medicinal Cannabis Evidence for Efficacy Clinical Guidance Deve...TGA Australia
 
Ольга Бермант-Полякова. Новейшие исследования в современной зарубежной психол...
Ольга Бермант-Полякова. Новейшие исследования в современной зарубежной психол...Ольга Бермант-Полякова. Новейшие исследования в современной зарубежной психол...
Ольга Бермант-Полякова. Новейшие исследования в современной зарубежной психол...Olga Bermant-Polyakova
 
Epidemiological study designs
Epidemiological study designsEpidemiological study designs
Epidemiological study designsIsmail Qamar
 
REVIEW Open AccessWhat happens after treatment Asystema.docx
REVIEW Open AccessWhat happens after treatment Asystema.docxREVIEW Open AccessWhat happens after treatment Asystema.docx
REVIEW Open AccessWhat happens after treatment Asystema.docxmichael591
 
Tapering Meta-Analysis Erin Krebs
Tapering Meta-Analysis Erin KrebsTapering Meta-Analysis Erin Krebs
Tapering Meta-Analysis Erin KrebsPaul Coelho, MD
 
Hlt 362 v Effective Communication / snaptutorial.com
Hlt 362 v  Effective Communication / snaptutorial.comHlt 362 v  Effective Communication / snaptutorial.com
Hlt 362 v Effective Communication / snaptutorial.comHarrisGeorg26
 
A systematic review of the quality of homeopathic clinical trials
A systematic review of the quality of homeopathic clinical trialsA systematic review of the quality of homeopathic clinical trials
A systematic review of the quality of homeopathic clinical trialshome
 
Critical appraisal.docx IMPORTAN TO HEALTH SCIENCE STUDENTS
Critical appraisal.docx IMPORTAN TO HEALTH SCIENCE STUDENTSCritical appraisal.docx IMPORTAN TO HEALTH SCIENCE STUDENTS
Critical appraisal.docx IMPORTAN TO HEALTH SCIENCE STUDENTSMulugetaAbeneh1
 
Randomised placebo-controlled trials of individualised homeopathic treatment:...
Randomised placebo-controlled trials of individualised homeopathic treatment:...Randomised placebo-controlled trials of individualised homeopathic treatment:...
Randomised placebo-controlled trials of individualised homeopathic treatment:...Francisco Navarro
 

Similaire à Journal Review: Rates of Treatment-Resistant Schizophrenia from First-Episode Cohorts - Systematic Review and Meta-Analysis (20)

Master of Public Health.pdf
Master of Public Health.pdfMaster of Public Health.pdf
Master of Public Health.pdf
 
Slone et al. 2105
Slone et al. 2105Slone et al. 2105
Slone et al. 2105
 
systematic review and metaanalysis
systematic review and metaanalysis systematic review and metaanalysis
systematic review and metaanalysis
 
Evidence based Practice in Emergency Medicine
Evidence based Practice in Emergency Medicine Evidence based Practice in Emergency Medicine
Evidence based Practice in Emergency Medicine
 
Christoph Correll
Christoph CorrellChristoph Correll
Christoph Correll
 
HLT 362V Inspiring Innovation/tutorialrank.com
 HLT 362V Inspiring Innovation/tutorialrank.com  HLT 362V Inspiring Innovation/tutorialrank.com
HLT 362V Inspiring Innovation/tutorialrank.com
 
HLT 362V Education Organization - snaptutorial.com
HLT 362V  Education Organization - snaptutorial.comHLT 362V  Education Organization - snaptutorial.com
HLT 362V Education Organization - snaptutorial.com
 
Christy Starr Denman Poster
Christy Starr Denman PosterChristy Starr Denman Poster
Christy Starr Denman Poster
 
Presentation: Medicinal Cannabis Evidence for Efficacy Clinical Guidance Deve...
Presentation: Medicinal Cannabis Evidence for Efficacy Clinical Guidance Deve...Presentation: Medicinal Cannabis Evidence for Efficacy Clinical Guidance Deve...
Presentation: Medicinal Cannabis Evidence for Efficacy Clinical Guidance Deve...
 
Ольга Бермант-Полякова. Новейшие исследования в современной зарубежной психол...
Ольга Бермант-Полякова. Новейшие исследования в современной зарубежной психол...Ольга Бермант-Полякова. Новейшие исследования в современной зарубежной психол...
Ольга Бермант-Полякова. Новейшие исследования в современной зарубежной психол...
 
Epidemiological study designs
Epidemiological study designsEpidemiological study designs
Epidemiological study designs
 
REVIEW Open AccessWhat happens after treatment Asystema.docx
REVIEW Open AccessWhat happens after treatment Asystema.docxREVIEW Open AccessWhat happens after treatment Asystema.docx
REVIEW Open AccessWhat happens after treatment Asystema.docx
 
Tapering Meta-Analysis Erin Krebs
Tapering Meta-Analysis Erin KrebsTapering Meta-Analysis Erin Krebs
Tapering Meta-Analysis Erin Krebs
 
Hlt 362 v Effective Communication / snaptutorial.com
Hlt 362 v  Effective Communication / snaptutorial.comHlt 362 v  Effective Communication / snaptutorial.com
Hlt 362 v Effective Communication / snaptutorial.com
 
10.1093@cid@cix505
10.1093@cid@cix50510.1093@cid@cix505
10.1093@cid@cix505
 
Research methodology
Research methodologyResearch methodology
Research methodology
 
Research methodology
Research methodologyResearch methodology
Research methodology
 
A systematic review of the quality of homeopathic clinical trials
A systematic review of the quality of homeopathic clinical trialsA systematic review of the quality of homeopathic clinical trials
A systematic review of the quality of homeopathic clinical trials
 
Critical appraisal.docx IMPORTAN TO HEALTH SCIENCE STUDENTS
Critical appraisal.docx IMPORTAN TO HEALTH SCIENCE STUDENTSCritical appraisal.docx IMPORTAN TO HEALTH SCIENCE STUDENTS
Critical appraisal.docx IMPORTAN TO HEALTH SCIENCE STUDENTS
 
Randomised placebo-controlled trials of individualised homeopathic treatment:...
Randomised placebo-controlled trials of individualised homeopathic treatment:...Randomised placebo-controlled trials of individualised homeopathic treatment:...
Randomised placebo-controlled trials of individualised homeopathic treatment:...
 

Plus de Robert Ferris

Measles - Clinical Refresher, February 2024
Measles - Clinical Refresher, February 2024Measles - Clinical Refresher, February 2024
Measles - Clinical Refresher, February 2024Robert Ferris
 
Journal Reviews - Benefits of Cold-Water Swimming, and the Wim Hof Method
Journal Reviews - Benefits of Cold-Water Swimming, and the Wim Hof MethodJournal Reviews - Benefits of Cold-Water Swimming, and the Wim Hof Method
Journal Reviews - Benefits of Cold-Water Swimming, and the Wim Hof MethodRobert Ferris
 
Journal Review: Venous Thromboembolism with use of Hormonal Contraception and...
Journal Review: Venous Thromboembolism with use of Hormonal Contraception and...Journal Review: Venous Thromboembolism with use of Hormonal Contraception and...
Journal Review: Venous Thromboembolism with use of Hormonal Contraception and...Robert Ferris
 
ECG of the Week - Hypokalaemia
ECG of the Week - HypokalaemiaECG of the Week - Hypokalaemia
ECG of the Week - HypokalaemiaRobert Ferris
 
Journal Review: Meta-Analysis - Low and Very-Low Carbohydrate Diets for Manag...
Journal Review: Meta-Analysis - Low and Very-Low Carbohydrate Diets for Manag...Journal Review: Meta-Analysis - Low and Very-Low Carbohydrate Diets for Manag...
Journal Review: Meta-Analysis - Low and Very-Low Carbohydrate Diets for Manag...Robert Ferris
 
Drug of the Week - Aspirin
Drug of the Week - AspirinDrug of the Week - Aspirin
Drug of the Week - AspirinRobert Ferris
 
Direct Ophthalmoscopy/Fundoscopy
Direct Ophthalmoscopy/FundoscopyDirect Ophthalmoscopy/Fundoscopy
Direct Ophthalmoscopy/FundoscopyRobert Ferris
 
Journal Review - REVERT Trial: Modified Valsalva for Supraventricular Tachyca...
Journal Review - REVERT Trial: Modified Valsalva for Supraventricular Tachyca...Journal Review - REVERT Trial: Modified Valsalva for Supraventricular Tachyca...
Journal Review - REVERT Trial: Modified Valsalva for Supraventricular Tachyca...Robert Ferris
 
Paediatric Foreign Body Aspiration
Paediatric Foreign Body AspirationPaediatric Foreign Body Aspiration
Paediatric Foreign Body AspirationRobert Ferris
 
Case Study - Acute Pancreatitis
Case Study - Acute PancreatitisCase Study - Acute Pancreatitis
Case Study - Acute PancreatitisRobert Ferris
 
Application for Medical Internship in Ireland for Graduates of Polish and Oth...
Application for Medical Internship in Ireland for Graduates of Polish and Oth...Application for Medical Internship in Ireland for Graduates of Polish and Oth...
Application for Medical Internship in Ireland for Graduates of Polish and Oth...Robert Ferris
 
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...Robert Ferris
 
Cancer of Unknown Primary Origin (CUP) and its relation to HPV-associated oro...
Cancer of Unknown Primary Origin (CUP) and its relation to HPV-associated oro...Cancer of Unknown Primary Origin (CUP) and its relation to HPV-associated oro...
Cancer of Unknown Primary Origin (CUP) and its relation to HPV-associated oro...Robert Ferris
 
Patient case - Persistent Upper Respiratory Tract Infection *RE-UPLOAD*
Patient case - Persistent Upper Respiratory Tract Infection *RE-UPLOAD*Patient case - Persistent Upper Respiratory Tract Infection *RE-UPLOAD*
Patient case - Persistent Upper Respiratory Tract Infection *RE-UPLOAD*Robert Ferris
 
Case Study - Leptospirosis
Case Study - LeptospirosisCase Study - Leptospirosis
Case Study - LeptospirosisRobert Ferris
 
Poster - Designing a new drug kardex to improve the quality of prescribing an...
Poster - Designing a new drug kardex to improve the quality of prescribing an...Poster - Designing a new drug kardex to improve the quality of prescribing an...
Poster - Designing a new drug kardex to improve the quality of prescribing an...Robert Ferris
 
Effects of the Yo-Yo IR1 as a HIIT tool on the Body Composition and Aerobic C...
Effects of the Yo-Yo IR1 as a HIIT tool on the Body Composition and Aerobic C...Effects of the Yo-Yo IR1 as a HIIT tool on the Body Composition and Aerobic C...
Effects of the Yo-Yo IR1 as a HIIT tool on the Body Composition and Aerobic C...Robert Ferris
 
Case study - suspicion of Cushing Syndrome (undiagnosed)
Case study - suspicion of Cushing Syndrome (undiagnosed)Case study - suspicion of Cushing Syndrome (undiagnosed)
Case study - suspicion of Cushing Syndrome (undiagnosed)Robert Ferris
 
Evaluation of Hearing in Children - from birth until 7 years old
Evaluation of Hearing in Children - from birth until 7 years oldEvaluation of Hearing in Children - from birth until 7 years old
Evaluation of Hearing in Children - from birth until 7 years oldRobert Ferris
 
Nutrition - Elite Female Teenage Golfer
Nutrition -  Elite Female Teenage GolferNutrition -  Elite Female Teenage Golfer
Nutrition - Elite Female Teenage GolferRobert Ferris
 

Plus de Robert Ferris (20)

Measles - Clinical Refresher, February 2024
Measles - Clinical Refresher, February 2024Measles - Clinical Refresher, February 2024
Measles - Clinical Refresher, February 2024
 
Journal Reviews - Benefits of Cold-Water Swimming, and the Wim Hof Method
Journal Reviews - Benefits of Cold-Water Swimming, and the Wim Hof MethodJournal Reviews - Benefits of Cold-Water Swimming, and the Wim Hof Method
Journal Reviews - Benefits of Cold-Water Swimming, and the Wim Hof Method
 
Journal Review: Venous Thromboembolism with use of Hormonal Contraception and...
Journal Review: Venous Thromboembolism with use of Hormonal Contraception and...Journal Review: Venous Thromboembolism with use of Hormonal Contraception and...
Journal Review: Venous Thromboembolism with use of Hormonal Contraception and...
 
ECG of the Week - Hypokalaemia
ECG of the Week - HypokalaemiaECG of the Week - Hypokalaemia
ECG of the Week - Hypokalaemia
 
Journal Review: Meta-Analysis - Low and Very-Low Carbohydrate Diets for Manag...
Journal Review: Meta-Analysis - Low and Very-Low Carbohydrate Diets for Manag...Journal Review: Meta-Analysis - Low and Very-Low Carbohydrate Diets for Manag...
Journal Review: Meta-Analysis - Low and Very-Low Carbohydrate Diets for Manag...
 
Drug of the Week - Aspirin
Drug of the Week - AspirinDrug of the Week - Aspirin
Drug of the Week - Aspirin
 
Direct Ophthalmoscopy/Fundoscopy
Direct Ophthalmoscopy/FundoscopyDirect Ophthalmoscopy/Fundoscopy
Direct Ophthalmoscopy/Fundoscopy
 
Journal Review - REVERT Trial: Modified Valsalva for Supraventricular Tachyca...
Journal Review - REVERT Trial: Modified Valsalva for Supraventricular Tachyca...Journal Review - REVERT Trial: Modified Valsalva for Supraventricular Tachyca...
Journal Review - REVERT Trial: Modified Valsalva for Supraventricular Tachyca...
 
Paediatric Foreign Body Aspiration
Paediatric Foreign Body AspirationPaediatric Foreign Body Aspiration
Paediatric Foreign Body Aspiration
 
Case Study - Acute Pancreatitis
Case Study - Acute PancreatitisCase Study - Acute Pancreatitis
Case Study - Acute Pancreatitis
 
Application for Medical Internship in Ireland for Graduates of Polish and Oth...
Application for Medical Internship in Ireland for Graduates of Polish and Oth...Application for Medical Internship in Ireland for Graduates of Polish and Oth...
Application for Medical Internship in Ireland for Graduates of Polish and Oth...
 
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...
Sarcopenia - identifying, measuring and managing muscle loss in elderly popul...
 
Cancer of Unknown Primary Origin (CUP) and its relation to HPV-associated oro...
Cancer of Unknown Primary Origin (CUP) and its relation to HPV-associated oro...Cancer of Unknown Primary Origin (CUP) and its relation to HPV-associated oro...
Cancer of Unknown Primary Origin (CUP) and its relation to HPV-associated oro...
 
Patient case - Persistent Upper Respiratory Tract Infection *RE-UPLOAD*
Patient case - Persistent Upper Respiratory Tract Infection *RE-UPLOAD*Patient case - Persistent Upper Respiratory Tract Infection *RE-UPLOAD*
Patient case - Persistent Upper Respiratory Tract Infection *RE-UPLOAD*
 
Case Study - Leptospirosis
Case Study - LeptospirosisCase Study - Leptospirosis
Case Study - Leptospirosis
 
Poster - Designing a new drug kardex to improve the quality of prescribing an...
Poster - Designing a new drug kardex to improve the quality of prescribing an...Poster - Designing a new drug kardex to improve the quality of prescribing an...
Poster - Designing a new drug kardex to improve the quality of prescribing an...
 
Effects of the Yo-Yo IR1 as a HIIT tool on the Body Composition and Aerobic C...
Effects of the Yo-Yo IR1 as a HIIT tool on the Body Composition and Aerobic C...Effects of the Yo-Yo IR1 as a HIIT tool on the Body Composition and Aerobic C...
Effects of the Yo-Yo IR1 as a HIIT tool on the Body Composition and Aerobic C...
 
Case study - suspicion of Cushing Syndrome (undiagnosed)
Case study - suspicion of Cushing Syndrome (undiagnosed)Case study - suspicion of Cushing Syndrome (undiagnosed)
Case study - suspicion of Cushing Syndrome (undiagnosed)
 
Evaluation of Hearing in Children - from birth until 7 years old
Evaluation of Hearing in Children - from birth until 7 years oldEvaluation of Hearing in Children - from birth until 7 years old
Evaluation of Hearing in Children - from birth until 7 years old
 
Nutrition - Elite Female Teenage Golfer
Nutrition -  Elite Female Teenage GolferNutrition -  Elite Female Teenage Golfer
Nutrition - Elite Female Teenage Golfer
 

Dernier

DR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in IndiaDR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in IndiaNehamehta128467
 
Denture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of actionDenture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of actionDr.shiva sai vemula
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Health Kinesiology Natural Bioenergetics
 
PYODERMA, IMPETIGO, FOLLICULITIS, FURUNCLES, CARBUNCLES.pdf
PYODERMA, IMPETIGO, FOLLICULITIS, FURUNCLES, CARBUNCLES.pdfPYODERMA, IMPETIGO, FOLLICULITIS, FURUNCLES, CARBUNCLES.pdf
PYODERMA, IMPETIGO, FOLLICULITIS, FURUNCLES, CARBUNCLES.pdfDolisha Warbi
 
Signs It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing WellnessSigns It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing WellnessGokuldas Hospital
 
Get the best psychology treatment in Indore at Gokuldas Hospital
Get the best psychology treatment in Indore at Gokuldas HospitalGet the best psychology treatment in Indore at Gokuldas Hospital
Get the best psychology treatment in Indore at Gokuldas HospitalGokuldas Hospital
 
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019Akash Agnihotri
 
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341Sherrylee83
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsMedicoseAcademics
 
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Night
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and NightVIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Night
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Nightpatanjali9823#S07
 
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptx
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptxANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptx
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptxDr. Sohan Biswas
 
ESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failureESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failuremahiavy26
 
Premium ℂall Girls In Mumbai👉 Dail ℂALL ME: 📞9833325238 📲 ℂall Richa VIP ℂall...
Premium ℂall Girls In Mumbai👉 Dail ℂALL ME: 📞9833325238 📲 ℂall Richa VIP ℂall...Premium ℂall Girls In Mumbai👉 Dail ℂALL ME: 📞9833325238 📲 ℂall Richa VIP ℂall...
Premium ℂall Girls In Mumbai👉 Dail ℂALL ME: 📞9833325238 📲 ℂall Richa VIP ℂall...Avani bhatt
 
CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...
CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...
CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...ocean4396
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATROKanhu Charan
 
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxThe Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxDr. Rabia Inam Gandapore
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxSamar Tharwat
 
HIFI* ℂall Girls In Thane West Phone 🔝 9920874524 🔝 💃 Me All Time Serviℂe Ava...
HIFI* ℂall Girls In Thane West Phone 🔝 9920874524 🔝 💃 Me All Time Serviℂe Ava...HIFI* ℂall Girls In Thane West Phone 🔝 9920874524 🔝 💃 Me All Time Serviℂe Ava...
HIFI* ℂall Girls In Thane West Phone 🔝 9920874524 🔝 💃 Me All Time Serviℂe Ava...Ishita Kashyap
 
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsHistology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsMedicoseAcademics
 

Dernier (20)

DR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in IndiaDR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in India
 
Denture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of actionDenture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of action
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
 
PYODERMA, IMPETIGO, FOLLICULITIS, FURUNCLES, CARBUNCLES.pdf
PYODERMA, IMPETIGO, FOLLICULITIS, FURUNCLES, CARBUNCLES.pdfPYODERMA, IMPETIGO, FOLLICULITIS, FURUNCLES, CARBUNCLES.pdf
PYODERMA, IMPETIGO, FOLLICULITIS, FURUNCLES, CARBUNCLES.pdf
 
Signs It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing WellnessSigns It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing Wellness
 
Get the best psychology treatment in Indore at Gokuldas Hospital
Get the best psychology treatment in Indore at Gokuldas HospitalGet the best psychology treatment in Indore at Gokuldas Hospital
Get the best psychology treatment in Indore at Gokuldas Hospital
 
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
 
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
 
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Night
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and NightVIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Night
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Night
 
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptx
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptxANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptx
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptx
 
ESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failureESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failure
 
Premium ℂall Girls In Mumbai👉 Dail ℂALL ME: 📞9833325238 📲 ℂall Richa VIP ℂall...
Premium ℂall Girls In Mumbai👉 Dail ℂALL ME: 📞9833325238 📲 ℂall Richa VIP ℂall...Premium ℂall Girls In Mumbai👉 Dail ℂALL ME: 📞9833325238 📲 ℂall Richa VIP ℂall...
Premium ℂall Girls In Mumbai👉 Dail ℂALL ME: 📞9833325238 📲 ℂall Richa VIP ℂall...
 
CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...
CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...
CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
 
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxThe Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
 
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
 
HIFI* ℂall Girls In Thane West Phone 🔝 9920874524 🔝 💃 Me All Time Serviℂe Ava...
HIFI* ℂall Girls In Thane West Phone 🔝 9920874524 🔝 💃 Me All Time Serviℂe Ava...HIFI* ℂall Girls In Thane West Phone 🔝 9920874524 🔝 💃 Me All Time Serviℂe Ava...
HIFI* ℂall Girls In Thane West Phone 🔝 9920874524 🔝 💃 Me All Time Serviℂe Ava...
 
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsHistology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
 

Journal Review: Rates of Treatment-Resistant Schizophrenia from First-Episode Cohorts - Systematic Review and Meta-Analysis

  • 1. SCHIZOPHRENIA FROM FIRST- EPISODE COHORTS: SYSTEMATIC REVIEW AND META-ANALYSIS Dr. Robert Ferris & Dr. Daere Akobo Journal Review
  • 2. Background  Lifetime prevalence of schizophrenia is 7 per 1000 people6  Not all patients respond to 1st line antipsychotic medication; poor response to treatment leads to a diagnosis of Treatment- Resistant Schizophrenia (TRS)  TRS is associated with high levels of functional impairment8, healthcare usage, societal costs9 and physical health comorbidity10
  • 3. Background  A consensus definition of TRS has been developed by the Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group3, which includes the following:  Current symptoms of at least moderate severity and moderate or worse functional impairment  Prior treatment with at least two different antipsychotics, each for at least 4–6 weeks minimum duration at total daily dose equivalent of at least 600mg chlorpromazine
  • 4. Treatment-Resistant Schizophrenia (TRS)  There remains a lack of clarity as to the proportion of patients with TRS  The most effective medication for TRS is clozapine, which offers  Improvement in positive symptoms7  Improved rates of hospital admissions11  Decreased overall mortality12  Clozapine use, due to its potential adverse-effects, is typically limited to patients who have had ≥2 previous failed responses to first-line antipsychotics  Implementation of clozapine therapy is, therefore, sometimes regarded as an indicator of TRS1  Regional differences in rates of clozapine prescribing negatively affects its use as a proxy for TRS rates
  • 6. The Study1  Quantifying the rates of patients with TRS may highlight the need to improve access to clozapine and increase opportunities of a clozapine trial for patients with TRS  Cross-sectional studies examining the proportion of patients with TRS may overestimate the true rate because of selection bias  In contrast, longitudinal first-episode cohort studies may more accurately quantify the incidence of patients with TRS  However, first-episode cohort studies from single sites may not be generalisable  Combination of first-episode cohorts from multiple sites provides more robust data set
  • 7. The Study1  Literature was systematically reviewed with this in mind  Longitudinal cohort studies of people with First- Episode Psychosis (FEP) and First-Episode Schizophrenia (FES)  The proportion that met criteria for TRS at follow-up were identified, then meta-analysis was performed in order to quantify rates of TRS
  • 8. Inclusion Criteria  Cohort studies of individuals with FEP or FES who were diagnosed according to DSM-IV, DSM-5 or ICD-10 classifications  Presence of clear definition of (TRS) consistent with the TRRIP Working Group’s standardised definition3  Presence of longitudinal information on pharmacological interventions  Reports on the proportion of the FEP/FES population who went on to develop a treatment-resistant form of the illness  Follow-up period of at least 8 weeks
  • 9. Exclusion Criteria  Papers with >75% overlap of included data-sets with another paper  Study populations which had already been exposed to previous antipsychotic treatment before entry into the cohort  Where substance-induced psychosis could not be excluded at time of follow-up  Study designs that did not specifically capture all sequential first-episode patients, such as cross- sectional or randomised controlled trials, were excluded as it could not be ascertained if the criteria for participation in these studies constituted a selection bias
  • 10. Methodology  Systematic review and meta-analysis  8,273 citations, ultimately yielding 12 clinical trials deemed fit for inclusion, including 1 unpublished data set  These studies covered a total of 11,958 individuals  Studies from Canada (n = 2), Denmark (n = 1), England (n = 2), Japan (n = 1), Turkey (n = 1), India (n = 1), USA (n = 1) and Ireland (n = 1); two studies had multiple international locations  Proportion of male study participants was 61.9% (SD 10.4%)
  • 11. Methodology  Median duration of follow-up 26 months (range 2–120 months)  Nine cohorts comprised participants with FES and three cohorts comprised participants with FEP  Nine studies used prospective data collection; data for the remaining three was collected retrospectively  Two studies provided data on involuntary treatment status
  • 13. Data Extraction and Publication Bias  Two authors independently extracted data, which was validated by two other authors from the research team  Publication bias was explored using funnel pot asymmetry testing for statistical significance with both Kendall’s τ and Egger’s regression when meta-analyses included ≥10 studies
  • 14. Results  Overall rate of TRS was 22.8% (95% CI 19.1–27.0%, P < 0.001, I2 = 91.8%)  Rates of TRS were significantly lower in FEP cohorts compared with FES cohorts (17.8% vs. 24.4%, P = 0.046)
  • 16. Discussion  Rate of TRS was 22.8% in combined FEP and FES cohorts, rising to 24.4% when only FES cohorts included  Rates of TRS were significantly lower in FEP cohorts compared with FES cohorts (17.8% vs. 24.4%, P = 0.046)
  • 17. Discussion  Men 1.5 times as likely as women to develop TRS (95% CI 1.11–2.21, P = 0.010, I2 = 74%)  In keeping with previous findings that men are one and a half times more likely to develop schizophrenia than women4  Males generally diagnosed at a younger age5
  • 18. Critical Appraisal  Measured using the Critical Appraisal Skills Programme (CASP) Checklist for Systematic Review13  10-question tool for appraisal of systematic review
  • 19. Section A: Are the results valid? 1. Did the review address a clearly focused question?  YES: the review sought to measure rates of TRS from FEP and FES presentations 2. Did the authors look for the right type of papers?  YES: All were cohort studies, appropriate for assessing single defined outcome from defined populations 3. Do you think all the important, relevant studies were included?  YES: The authors utilised several different databases; PubMed, PsycINFO, EMBASE, CINAHL and the Cochrane Database of Systematic Reviews, including unpublished data
  • 20. Section A: Are the results valid? 4. Did the review’s authors do enough to assess quality of the included studies?  YES: Studies were assessed as low risk of bias and high strength of reporting (three or more points), or high risk of bias and low strength of reporting (fewer than three points) using modified Newcastle–Ottawa Scale  Six of twelve included studies were deemed to be of high quality  Only English-language studies were used 5. If the results of the review have been combined, was it reasonable to do so?  CAN’T TELL: All were similar study types, examining common outcomes  However, there was a mix of prospective and retrospective used (retrospective more prone to bias)
  • 21. Section B: What are the results? 6. What are the overall results of the review?  As previously-described, rates of TRS are provided as percentage values of measured cohorts, and also divided based on FEP vs. FES presentations  Overall rate of TRS was 22.8%  Rates of TRS in FEP cohorts 17.8% vs. 24.4% in FES cohorts 7. How precise are the results?  95% CI 19.1–27.0%, P < 0.001, I2 = 91.8%  Study examines progression from both FEP and FES only: rates of TRS in those with pre-existing diagnoses not captured
  • 22. Section C: Will the results help locally? 8. Can the results be applied to the local population?  YES: authors posit that “Early identification of people with FES who fail to respond to first or second antipsychotic trials can assist in timely provision of evidence-based treatments for TRS such as clozapine”  In Ireland, clozapine treatment is widely available, and its use may be considered a reliable indicator for TRS  These results indicate benefits of prompt use  However, potential contributing factors which may
  • 23. Section C: Will the results help locally? 9. Were all important outcomes considered?  CAN’T TELL: Contributors of lost-to-follow-up cohort? Concomitant diagnoses? Involuntary admission status?  Unclear to what extent these would effect outcomes 10. Are the benefits worth the harms and costs?  YES: Meta-analysis of TRS rates from first presentation  No harms/costs apparent from measurement alone
  • 24. Reference s 1. Siskind D., Orr S. et al. (2022), ‘Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis’, BJPsych 220: 115–120. doi: 10.1192/bjp.2021.61 2. Psycom.net, ‘Schizophrenia’, accessed at https://www.psycom.net/schizophrenia on 12/05/2022 3. Howes O.D., McCutcheon R. et al. (2017), ‘Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology’, Am J Psychiatry 174(3): 216–29 4. Aleman A., Kahn R.S., Selten J-P. (2003), ‘Sex differences in the risk of schizophrenia: evidence from meta-analysis’, Arch Gen Psychiatry 60(6): 565–71 5. Sommer I.E., Tiihonen J et al. (2020), ‘The clinical course of schizophrenia in women and men—a nation-wide cohort study’, NPJ Schizophr 6: 12 6. Saha S., Chant D. et al. (2005), ‘A systematic review of the prevalence of schizophrenia’, PLoS Med 2(5): e141 7. Siskind D., McCartney L. et al. (2016), ‘Clozapine v. first-and second generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis’, Br J Psychiatry 209(5): 385–92 Thank you.
  • 25. References (contd.) 8. Lasevoli F., Giordano S. et al. (2016), ‘Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly- disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones’, Prog Neuropsychopharmacol Biol Psychiatry 65: 34–48 9. Kennedy J.L., Altar C.A. et al. (2014), ‘The social and economic burden of treatment-resistant schizophrenia: a systematic literature review’, Int Clin Psychopharmacol 29(2): 63–76 10. Firth J., Siddiqi N. et al. (2019), ‘The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness’, Lancet Psychiatry 6(8): 675–712 11. Land R., Siskind D. et al. (2017), ‘The impact of clozapine on hospital use: a systematic review and meta-analysis’, Acta Psychiatr. Scand. 135(4): 296–309 12. Vermeulen J.M., van Rooijen G. et al. (2019), ‘Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years’, Schizophr Bull 45(2): 315–29 13. Critical Appraisal Skills Programme (2018), ‘CASP Systematic Review Checklist’, accessed at https://casp-uk.b-cdn.net/wp-content/uploads/2018/03/CASP- Systematic-Review-Checklist-2018_fillable-form.pdf on 23/05/2022 Thank you.